Coherus Biosciences: Dumping One Drug But Showing Promise With Another

MCCAIG/iStock via Getty Images Coherus Biosciences (NASDAQ:CHRS) has a pipeline of marketed drugs, including a new drug and biosimilars, but also a developmental pipeline. When I wrote about CHRS in January, I rated it a hold, noting a near-term catalyst of updated clinical data from casdozokitug in liver cancer, the launch of a new biosimilar product and the launch of its new drug. This article takes a look at the new clinical data and developments since, which have led me to upgrade my rating from hol ...